Akamis Bio
akamisbio.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$60M
1 round on record
Latest round
$60M
Series A · Dec 2024 · 21 mo ago
Backers
2
ARCH Venture Partners, SR One
The money's age
Due for its next round
21 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Dec 20, 2024
Raised a round Series A $60M · Pulse 2.0
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Dec 2024 | $60M | — | Pulse 2.0 |
Registers and programsofficial lists and records that name the company
| Legal entity | Akamis Bio, Inc. | its site |
Backed byfrom the funds' portfolios and accelerator catalogs
ARCH Venture Partners 
SR One Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
MiWEndo Solutions enhances early detection of colorectal cancer with innovative technology. We transform colonoscopies to provide more…
Odyssey is on a mission to transform the standard of care for patients affected by autoimmune and inflammatory conditions.
Developer of breakthrough biotherapeutics for B cell cancers, metabolic diseases, and chronic hepatitis B infections.
Advancing novel therapies to restore the health of gastrointestinal tissues. Curileum is developing novel therapies that restore the health…
T cell Based Immunotherapies for Cancer and Chronic Infectious Diseases.
From IVL to coronary sinus reduction, Shockwave Medical is transforming standards of care and driving better outcomes for underserved…
News
Akamis Bio Announces Encouraging Preliminary Results from the Phase 1b FORTRESS Study of NG-350A in Mismatch Repair-Proficient Locally Advanced Rectal Cancer
CAMBRIDGE, Mass., April 17, 2026--Akamis Bio, a clinical-stage oncology company working to advance the standard of care in colorectal cancer, today announced early data from the on-going Phase 1b FORTRESS study of NG-350A, an oncolytic immunotherapy for t
Read more
Report
Akamis Bio to Present Initial Data from the Phase 1b FORTRESS Study of NG-350A in Mismatch Repair-Proficient Locally Advanced Rectal Cancer at AACR 2026
CAMBRIDGE, Mass., March 17, 2026--Akamis Bio, a clinical-stage oncology company working to advance the standard of care in colorectal cancer, today announced an upcoming poster presentation of initial clinical data from the FORTRESS study of NG-350A, an o
Read more
Report
Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing! The post Hello world! appeared first on Akamis Bio.
Read more
Report
Akamis Bio: $60 Million Raised For Developing Solid Tumor Treatments
Akamis Bio - a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene (T-SIGn) therapy platform to deliver novel immunotherapeutic proteins, biomolecules, and transgene combinations to treat solid tumors - announced $60 million in
Read more
Report
Akamis Bio: Tumor-Specific Immuno-Gene Company Closes$60 Million (Series A)
Akamis Bio - a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene (T-SIGn) therapy platform to deliver novel immunotherapeutic proteins, biomolecules, and transgene combinations to treat solid tumors - announced $60 million in
Read more
Report
Akamis Bio Announces Publication Detailing Initial Proof of Mechanism for NG-350A, an IV-Dosed Tumor Gene Therapy Delivering a CD40 Agonist Payload
Read more
Report
Report
Akamis Bio, Parker Institute for Cancer Immunotherapy, and Cancer Research Institute Announce Expanded Partnership to Advance Novel Treatments for Pancreatic Cancer
Akamis Bio's clinical-stage NG-350A tumor gene therapy to be included as a novel combination therapeutic agent in a new cohort of the REVOLUTION platform study New cohort will assess the ability of
Read more
Report
Financials
Total raised
$60M
Latest round
Series A
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series A | 2024 | $60M | Details |